Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide more accessible in India. This collaboration follows the upcoming expiry of Novo Nordisk's patent. Lupin will co-market Zydus's semaglutide injection under its own brand. This move aims to reach more patients across the country.